DTG50mg+3TC300mg+TDF300mg tab/180 No CTN

General description:
Dolutegravir 50mg + Lamivudine 300mg + Tenofovir disoproxil fumarate 300mg tablets in a bottle pack of 180 without carton

Technical specifications:
Each tablet contains Dolutegravir 50mg + Lamivudine 300mg + Tenofovir disoproxil fumarate 300mg which is equivalent to 245mg of Tenofovir Disoproxil as fixed dose combination (FDC).

Therapeutic class:
Dolutegravir is an Integrase Inhibitor
Lamivudine is a Nucleoside Reverse Transcriptase Inhibitors (NRTI).
Tenofovir is a Nucleotide Reverse Transcriptase Inhibitor (NtRTI)

Indications:
Management of HIV infection in children and adults. Administration by mouth (oral), PO.

Guidelines for use
For more details, please click the links listed below:

http://www.who.int/h iv/pub/guidelines/en/

http://www.who .int/selection_medicines/list/en/

or your regional national guidelines

For details about paediatric dosage schemes, please click the links listed below:

http://www.who.in t/hiv/topics/paediatric/en/

http://www.w ho.int/hiv/paediatric/generictool/en/


Shelf life:
24 months

Storage and transportation:
Do not store above 30ºC, protect from light.
Store in tightly closed original container.
Keep out of reach and sight of children.

Alternative products:
S1400647DTG50mg+3TC300mg+TDF300mg tab/30 No CTN
S1400648DTG50mg+3TC300mg+TDF300mg tab/90 No CTN
S1400652DTG50mg+3TC300mg+TDF300mg tabs/PAC-30 gb